Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Thomas Jefferson University
Nantes University Hospital
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
Wake Forest University Health Sciences
Massachusetts General Hospital
UNC Lineberger Comprehensive Cancer Center
University of Utah
Mayo Clinic
Calibr, a division of Scripps Research
Fred Hutchinson Cancer Center
Memorial Sloan Kettering Cancer Center
Alliance for Clinical Trials in Oncology
Ohio State University Comprehensive Cancer Center
Georgetown University
Memorial Sloan Kettering Cancer Center
Ohio State University Comprehensive Cancer Center
Hackensack Meridian Health
M.D. Anderson Cancer Center
University Hospital, Caen
University Hospital, Caen
University Hospital, Toulouse
Dana-Farber Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
University of Nebraska
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Medical University of South Carolina
City of Hope Medical Center
Mayo Clinic
Roswell Park Cancer Institute
Dana-Farber Cancer Institute
Abramson Cancer Center at Penn Medicine
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Gruppo Italiano Malattie EMatologiche dell'Adulto
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
City of Hope Medical Center
Masonic Cancer Center, University of Minnesota
University of Chicago
City of Hope Medical Center
M.D. Anderson Cancer Center
Massachusetts General Hospital
M.D. Anderson Cancer Center
University of Washington
City of Hope Medical Center
M.D. Anderson Cancer Center